TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25408735
Drug: Clarithromycin (2×500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (2×500 mg) + Amoxicillin (2×1 gr) + Omeprazole (2×20 mg) for 14 days
Study: 25408735
Drug: Azithromycin (1×250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (1×250 mg) + Amoxicillin (2×1 gr) + Omeprazole (2×20 mg) for 10 days
Study: 17698978
Drug: Individualized herbal
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized herbal treatment from qualified herbal practitioners (n = 15), six consultations over 5 months
Study: 17698978
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n = 30) offered treatment after waiting 4 months
Study: 17698978
Drug: Individualized herbal
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized herbal treatment
Study: 9932956
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose interferon beta-1b (8.0 mIU)
Study: 9932956
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose interferon beta-1b (1.6 mIU)
Study: 7586436
Drug: Preoperative steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative steroid (Solumedrol 250 mg IV, n = 16)
Study: 7586436
Drug: No steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No steroid (n = 9, control group)
Study: 2310577
Drug: Caudal analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal analgesia with bupivacaine (three different dosage regimens)
Study: 31540980
Drug: Lifastuzumab vedotin
Normalized name: Lifastuzumab vedotin
DrugBank: Lifastuzumab vedotin (DB15400)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifastuzumab vedotin (LIFA) at 2.4 mg/kg once every 3 weeks
Study: 31540980
Drug: Lifastuzumab vedotin
Normalized name: Lifastuzumab vedotin
DrugBank: Lifastuzumab vedotin (DB15400)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifastuzumab vedotin (LIFA) at doses ≥1.8 mg/kg
Study: 30722014
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g milk protein concentrate
Study: 30722014
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g milk protein concentrate
Study: 30722014
Drug: 45 g
Normalized name: SODIUM CHLORIDE 0.045 g in 5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 g milk protein concentrate
Study: 22326504
Drug: 0.75 mg
Normalized name: propinox 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg atrasentan
Study: 22326504
Drug: 1.75 mg
Normalized name: glyburide 1.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.75 mg atrasentan
Study: 22326504
Drug: 0.75 mg
Normalized name: propinox 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg atrasentan (Hispanic subjects)
Study: 22326504
Drug: 0.75 mg
Normalized name: propinox 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg atrasentan (non-Hispanic subjects)
Study: 22326504
Drug: Maximum doses
Normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maximum doses of RAS inhibitors
Study: 20191466
Drug: Communication about
Normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Communication about medication costs during visits
Study: 17412530
Drug: 1MIRP (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1MIRP (4 weekly individual sessions of motivational interviewing and relapse prevention over 1 month)
Study: 17412530
Drug: 3MIRP (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3MIRP (4 weekly individual sessions of motivational interviewing and relapse prevention over 3 months)
Study: 17412530
Drug: DTC (Delayed
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTC (Delayed Treatment Control)
Study: 12154111
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II infusion (3 ng/kg per minute for 45 minutes) and captopril during low salt balance
Study: 10834508
Drug: Myeloablative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myeloablative therapy followed by allogeneic stem-cell infusion
Study: 8823101
Drug: Heparin-coated circuit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated circuit (Duraflo II), n = 107
Study: 2994148
Drug: Enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 20 mg every morning for 14 days
Study: 30832742
Drug: IgGAM infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgGAM infusions for 5 days
Study: 30832742
Drug: Standard-of-care treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care treatment (SoC)
Study: 30212438
Drug: Integrated smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated smoking cessation intervention (QUIT) - 9-week program with 1 psychoeducation session and 9 weekly 1-hour sessions of cognitive behavioral therapy plus nicotine replacement therapy.
Study: 30212438
Drug: Enhanced standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced standard smoking intervention (ETAU) - 9-week program with 1 psychoeducation session and 4 brief weekly check-in sessions plus nicotine replacement therapy.
Study: 27097348
Drug: 7‐valent pneumococcal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7‐valent pneumococcal conjugate vaccine (7vCRM) + DTPa‐IPV‐Hib
Study: 22417026
Drug: Ketofol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketofol (1 mg/kg; 0.5 mg/kg propofol plus 0.5 mg/kg ketamine)
Study: 10843434
Drug: Inhaled steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled steroid (budesonide) for 6 weeks
Study: 10843434
Drug: Inhaled beta2‐agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beta2‐agonist (terbutaline) for 6 weeks followed by inhaled steroid for 2 weeks
Study: 28953631
Drug: TPVBRA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPVBRA with 20 mL 0.25% bupivacaine + 1 μg/kg dexmedetomidine
Study: 28953631
Drug: TPVBRA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPVBRA with 20 mL 0.25% bupivacaine
Study: 25955980
Drug: 1.5% Topical
Normalized name: ZILXI 1.5% Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% Topical Diclofenac
Study: 23369038
Drug: Paracetamol 1,000 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1,000 mg sustained release (SR) tablets
Study: 23369038
Drug: Conventional paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional paracetamol 500 mg tablets
Study: 21208923
Drug: Heterotypic vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heterotypic vaccine
Study: 19353315
Drug: Biological dressing
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological dressing (Xenoderm)
Study: 15161118
Drug: Rivastigmine 3-6
Normalized name: rivastigmine 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine 3-6 mg/day
Study: 15161118
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus nimodipine
Study: 11465702
Drug: Disease-Modifying Antirheumatic
Normalized name: ANTIRHEUMATICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease-Modifying Antirheumatic Drugs (DMARDs)
Study: 9570492
Drug: Antidepressants treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants treatment for 5 weeks
Study: 9570492
Drug: Non-responders to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-responders to antidepressants
Study: 8068589
Drug: Patient controlled
Normalized name: PATIENT CONTROLLED ANALGESIA VIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient controlled infusion of midazolam
Study: 8068589
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of midazolam
Study: 3059852
Drug: 0.075 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.075 mg.kg‐1 midazolam intravenously 3 to 5 min prior to induction with fentanyl (5 micrograms.kg‐1.min‐1)
Study: 28276901
Drug: HolisFiit®, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: HolisFiit®, a polyphenol-rich food supplement, daily supplementation for 16 weeks
Study: 25976046
Drug: Blood glucose
Normalized name: Blood Glucose Book
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood glucose levels of 4.4 to 6.1 mmol/L (Group A)
Study: 25976046
Drug: Blood glucose
Normalized name: Blood Glucose Book
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood glucose levels of 6.1 to 8.3 mmol/L (Group B)
Study: 25976046
Drug: Blood glucose
Normalized name: Blood Glucose Book
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood glucose levels of 8.3 to 10.0 mmol/L (Group C)
Study: 18836440
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin or norepinephrine re‐uptake inhibitors after training
Study: 7957836
Drug: Nebulized frusemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized frusemide (40 mg)
Study: 3602414
Drug: Amineptine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amineptine treatment
Study: 31230500
Drug: Nonwarfarin oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonwarfarin oral anticoagulants (NOACs)
Study: 28623954
Drug: Alirocumab 150
Normalized name: alirocumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 150 mg SC Q4W
Study: 28623954
Drug: Alirocumab 150
Normalized name: alirocumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 150 mg SC Q2W
Study: 23391342
Drug: Clonidine150 (Bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine150 (Bupivacaine 0.5% + 150 μg of clonidine)
Study: 23391342
Drug: Clonidine250 (Bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine250 (Bupivacaine 0.5% + 250 μg of clonidine)
Study: 11986408
Drug: Etanercept (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (25 mg, twice-weekly subcutaneous injections)
Study: 7619892
Drug: CGS 13429A
Normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGS 13429A (0.1 to 10 mg)
Study: 2196520
Drug: Methylphenidate 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 0.3 mg/kg twice a day
Study: 2196520
Drug: Methylphenidate 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 0.5 mg/kg twice a day
Study: 24640648
Drug: Statokinesitherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statokinesitherapy with biological feedback
Study: 21228334
Drug: Lenalidomide 25
Normalized name: lenalidomide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 25 mg orally on days 1-21 every 28 days until progression or as tolerated
Study: 17030175
Drug: Oral norfloxacin
Normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral norfloxacin (400 mg twice daily)
Study: 17030175
Drug: Intravenous ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ceftriaxone (1 g/day)
Study: 12575375
Drug: Qidan Tongmai
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Qidan Tongmai tablet (QDTMT) in Group A (33 cases without HLC)
Study: 12575375
Drug: Qidan Tongmai
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Qidan Tongmai tablet (QDTMT) in Group B (33 cases with HLC)
Study: 3576521
Drug: Aspirin 10
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 10 mg daily for 3 weeks
Study: 3576521
Drug: Aspirin 30
Normalized name: aspirin 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 30 mg daily for 3 weeks
Study: 3576521
Drug: Aspirin 10
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 10 mg and 30 mg
Study: 28467150
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (120 mg via nasogastric tube for 15 days)
Study: 27225859
Drug: 0.005 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.005 mg/kg glycopyrrolate
Study: 24856612
Drug: Once-daily glargine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily glargine
Study: 22747603
Drug: Chlorhexidine gel
Normalized name: chlorhexidine Oral Gel
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine gel (CHX-gel) (5.0%)
Study: 22747603
Drug: Octenidine gel
Normalized name: octenidine
DrugBank: Octenidine (DB12624)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octenidine gel (OCT-gel) (5.0%)
Study: 16927283
Drug: Pegylated interferon-alpha
Normalized name: Pegylated interferon alpha-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pegylated interferon-alpha plus ribavirin (treatment for persistent HCV infection)
Study: 8479129
Drug: Antioxidant therapy
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant therapy with two ampoules of Omnibionta (vitamins C, E, A, and B complex) diluted in 500 ml physiological sodium chloride, infused intravenously prior to reperfusion onset.
Study: 8479129
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antioxidant therapy).
Study: 8479129
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between therapy and control groups one hour after reperfusion.
Study: 3310159
Drug: Theophylline (TH;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (TH; 234 mg)
Study: 3310159
Drug: Neo-Biphyllin (NB;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neo-Biphyllin (NB; 600 mg)
Study: 25995322
Drug: Sildenafil 20
Normalized name: sildenafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 20 mg, three times daily for 12 weeks
Study: 24742755
Drug: Contextual factor:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contextual factor: treatment study phase
Study: 23319574
Drug: Pomalidomide (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide (4 mg) on days 1 to 21 (arm 21/28) plus weekly dexamethasone
Study: 23319574
Drug: Pomalidomide (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide (4 mg) continuously (arm 28/28) plus weekly dexamethasone
Study: 19961914
Drug: Chios mastic
Normalized name: Thymus mastichina flowering top oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chios mastic gum 350 mg three times daily
Study: 17340612
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment (CBT) group
Study: 15206735
Drug: Tryptophan (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tryptophan (1 g after each meal for 12 days)
Study: 10339997
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural injection of 1 ml (7 mg) bethametason in 10 ml normal saline and 20 ml local anesthetic (Lignocaine 1%)
Study: 10339997
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural injection of 20 ml local anaesthetic (Lignocaine 1%) and 10 ml normal saline
Study: 10339997
Drug: Superficial injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superficial injection of 1 ml (7 mg) bethametason around the sacral hiatus
Study: 7676778
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg 0.5% bupivacaine
Study: 7676778
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg 0.5% bupivacaine
Study: 7676778
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (25 mg and 30 mg)
Study: 31027084
Drug: Prolonged anticoagulation
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged anticoagulation therapy (median duration: 72.6 hours)
Study: 31027084
Drug: Brief anticoagulation
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief anticoagulation therapy (median duration: 5 hours)
Study: 31027084
Drug: Prolonged anticoagulation
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged anticoagulation therapy
Study: 31027084
Drug: Brief anticoagulation
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief anticoagulation therapy
Study: 28110155
Drug: RO5046013 (PEGylated
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO5046013 (PEGylated recombinant human insulin-like growth factor-I)
Study: 28110155
Drug: rhIGF‐I (unmodified
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIGF‐I (unmodified recombinant human insulin-like growth factor-I)
Study: 26499007
Drug: Drotaverine hydrochloride
Normalized name: drotaverine hydrochloride
DrugBank: Drotaverine (DB06751)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drotaverine hydrochloride (20 mg syrup for ages 4-6, 40 mg tablet for ages >6)
Study: 19621678
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of two mononucleotide markers (BAT26 and BAT25)
Study: 15579778
Drug: Prednisone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (0.5 mg/kg.d)
Study: 8431411
Drug: Arthroscopic surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthroscopic surgery followed by post-operative physical therapy (n = 9)
Study: 8431411
Drug: Non-surgical treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical treatment (n = 12)
Study: 3608730
Drug: Loperamide (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide (16 mg per os)
Study: 3608730
Drug: Loperamide (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide (16 mg per os) followed by naloxone (16 mg)
Study: 3608730
Drug: Loperamide (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide (16 mg per os) followed by naloxone (32 mg)
Study: 29310611
Drug: Oxaliplatin +
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin + S-1 (oxaliplatin dose of 130 mg/m2)
Study: 21129714
Drug: Bisoprolol (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (1.25 mg once daily)
Study: 21129714
Drug: Carvedilol (3.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (3.125 mg twice daily)
Study: 18353086
Drug: Surface preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surface preparation (gentle curettage or abrasion with a spatula)
Study: 15080820
Drug: Butterbur (BB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butterbur (BB) 50 mg twice daily
Study: 1812440
Drug: Norwegian meningococcus
Normalized name: MENINGOCOCCAL B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norwegian meningococcus B vaccine
Study: 26731173
Drug: Therapist-guided internet-delivered
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-guided internet-delivered acceptance-based behaviour therapy
Study: 2529892
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg b.d.
Study: 2529892
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate 100 mg t.d.s.
Study: 4692674
Drug: Hibiscrub (4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hibiscrub (4% chlorhexidine detergent solution)
Study: 4692674
Drug: Dermofax (0.75%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermofax (0.75% chlorhexidine detergent solution)
Study: 4692674
Drug: Disadine scrub
Normalized name: Scrub-Stat
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disadine scrub (povidone iodine detergent preparation)
Study: 4692674
Drug: Hibiscrub (4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hibiscrub (4% chlorhexidine detergent solution) after six applications
Study: 4692674
Drug: Dermofax (0.75%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermofax (0.75% chlorhexidine detergent solution) after six applications
Study: 24698702
Drug: Wet-wrap treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wet-wrap treatment (WWT) with diluted corticosteroids (1:3 mometasone furoate 0.1% ointment and for the face 1:19 mometasone furoate 0.1% ointment under a mask)
Study: 24698702
Drug: Emollient (petrolatum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emollient (petrolatum 20% in cetomacrogol cream)
Study: 24698702
Drug: Wet-wrap treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wet-wrap treatment (WWT) with diluted corticosteroids
Study: 23588625
Drug: L-Cat intervention
Normalized name: cat hair extract
DrugBank: Felis catus hair (DB10499)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Cat intervention
Study: 20716244
Drug: Concomitant ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Concomitant ibuprofen and paracetamol
Study: 18069745
Drug: Chemotherapy added
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy added to locoregional treatment
Study: 16360564
Drug: Electronic survey
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic survey (tablet)
Study: 12846755
Drug: rhIGF-1 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhIGF-1 (100 mg/kg subcutaneously twice a day for 6 days)
Study: 11158455
Drug: Cholesterol-lowering dietary
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol-lowering dietary intervention promoting adherence to a diet with 28% of energy from total fat, <8% from saturated fat, up to 9% from polyunsaturated fat, and <75 mg/1000 kcal cholesterol per day
Study: 9047258
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose chemotherapy followed by infusion of autologous hematopoietic stem cells and growth factors
Study: 9047258
Drug: Standard adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard adjuvant therapies
Study: 3036259
Drug: Metergoline 4
Normalized name: metergoline 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metergoline 4 mg